Data as of Jul 25
| +0.20 / +1.38%|
Osiris Therapeutics, Inc. is a stem cell company, which focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets. The company operates its business through two segments: Therapeutics and Biosurgery segment. The Therapeutics segment focuses on developing biologic stem cell drug candidates from readily available and non-controversial sources. The segment, using mesenchymal stem cell technology offers two biologic drug candidates, Prochymal and Chondrogen which has anti-inflammatory properties. The Biosurgery segment works to harness the ability of cells and novel constructs to promote the body's natural healing. The segment manufactures, markets and distributes Grafix and Ovation for tissue repair. Osiris Therapeutics was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD.
|Lode Debrabandere||President, Chief Executive Officer, COO & Director|
|Philip R. Jacoby||Chief Financial Officer, Secretary & Treasurer|
|Alla Danilkovitch||Vice President-Research & Development|
|Douglas Jacobstein||Senior Medial Director|
|Frank D. Czworka||Vice President & General Manager-Wound Care|